A Deep Dive Into the Investigational Alzheimer’s Drug Donanemab | LiveTalk | Being Patient

Being Patient speaks with Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, about the development of Eli Lilly’s investigational anti-amyloid drug donanemab, which recently received the FDA's breakthrough therapy designation. Weidman, principal investigator of two donanemab trials, shares insights on the drug’s trial data so far, and on what’s next for donanemab.
We rely on donations to bring you the latest research on dementia and brain health and to support our amazing team of independent journalists. Please consider donating to support of our mission of giving people impacted by dementia a better resource and connection to experts at the forefront of research. Our audience has grown so rapidly; we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs.
beingpatient.nationbuilder.com/
---------------------------------------------------------------------------------------------------------------
Stay connected on social media:
To catch our Brain Talks live, join our Facebook page:
/ beingpatient. .
To learn more about us, follow us on Instagram:
@beingpatientvoices
For the latest news on dementia research and lifestyle tips, visit our site:
www.beingpatient.com/

[@bathsheba9581]

Beta amyloid plaque is not the problem. When I reviewed the "nun's study", I came to the conclusion that our researchers were on the wrong path and have remained on this misguided path for many years now. I guess they've realized it now and they seem truly lost and disoriented with the new understanding.

[@polsen114]

Do you know what the right path is?

[@user-qe6bl1lb7u]

In the land of the blind, the one-eyed man is king. I have ADz, I will take the best available now and hope for better in future.